提醒

提醒专业图表

Beta Bionics Inc. (BBNX)

NasdaqGM: BBNX · 实时价格 · USD

17.57

-0.51 (-2.82%)

收盘价： Aug 14, 2026, 3:59 PM

18.48

+5.18%

盘后: 7:34 PM

-2.82% (1D)

买价	10.42
市值	790.47M
营收（TTM）	119.01M
净利润（TTM）	-72.97M
贝塔值	n/a
每股收益（TTM）	-1.6
市盈率（TTM）	n/a
预期市盈率	-7.59
市净率（TTM）	3.08
市销率（TTM）	6.64
Earnings Date	Oct 27, 2026

卖价	17.63
成交量	934,823
20日均量	1,112,257
开盘价	18.12
前收盘价	18.08
日内区间	17.49 - 18.15
52周区间	8.80 - 32.71
分析师	Buy
目标价	20 (13.83%)
分红	n/a
除息日	n/a

关于 BBNX

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adher...

[阅读更多]

行业 Medical Devices

板块 Healthcare

上市日期 Jan 30, 2025

员工人数 420

交易所 NasdaqGM

股票代码 BBNX

官网 https://www.betabionics.com

公司完整简介

财务表现

2025年，Beta Bionics的营收为100.25M，较上一年的65.12M增长53.94%。净利润为-73.2M，增长33.68%。

财务报表

分析师预测

根据11位分析师的评级，BBNX的平均评级为“Buy”。12个月目标价为20，较最新价格上涨空间13.83%。

股票预测

财报意外

Beta Bionics 已于 Jul 29, 2026 发布季度财报：

营收为 $32.01M 低于预期 $0, ， 37.76% 同比增长.

每股收益为 -0.36 超出预期 0.20, ， -33.33% 同比下滑.

下次财报发布时间

Beta Bionics Inc. 计划于以下时间发布财报 Oct 27, 2026, 收盘后。
分析师预计营收为 ... 升级

新闻

1周前 · Motley Fool

Beta Bionics (BBNX) Q2 2026 Earnings Call Transcript

Pharmacy channel sales surged 153% as new patient starts accelerated.

2周前 · Moby

Beta Bionics, Inc. Q2 2026 Earnings Call Summary

Moby summary of Beta Bionics, Inc.'s Q2 2026 earnings call

2周前 · MarketBeat

Beta Bionics Q2 Earnings Call Highlights

Beta Bionics (NASDAQ:BBNX) reported second-quarter 2026 net sales of $32 million, up approximately 38% from a year earlier, as new patient starts and recurring pharmacy-channel supply revenue supporte...

2周前 · Zacks

Beta Bionics, Inc. (BBNX) Reports Q2 Loss, Tops Revenue Estimates

Beta Bionics, Inc. (BBNX) delivered earnings and revenue surprises of +14.52% and +2.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2周前 · Simply Wall St.

Beta Bionics (BBNX) Stock Fair Value Falls As Medtech Reset Tempers iLet And Mint Optimism

The fair value estimate for Beta Bionics has moved from US$31.30 to US$19.80 per share, which places it closer to the current cluster of analyst price targets between US$13 and US$22. Recent commentar...

第 1 页，共 2 页

Beta Bionics Inc. (BBNX)